idiopathic pulmonary fibrosis Idiopathic pulmonary fibrosis IPF Idiopathic interstitial pneumonia Fibrosing alveolitis
Conditions
Interventions
Other
Sponsors
Thoracic Society of Thailand under Royal Patronage
Boehringer Ingelheim
Eligibility
Sex/Gender
All
Age
40 Years to 150 Years
Inclusion criteria
Inclusion criteria: 1. Physician review the diagnosis of IPF patients during the last 6 months before inclusion, based upon recent ATS/ERS/JRS/ALAT guidelines 2011 2. Age ≥ 40 years 3. Thai nationality with fluency in Thai conversation 4. Signed informed consent 5. Patient with further follow-up possible with enrolling investigator during planned study period
Exclusion criteria
Exclusion criteria: 1. Lung transplantation expected within the next 6 months 2. Inclusion in ongoing clinical trials 3. Cannot provide a signed informed consent and cannot be followed up by investigator within study duration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Forced vital capacity (FVC) Baseline, month 3, 6 , 9, 12, 18, and 24 percent of predicted value,Annual rate of decline of forced vital capacity (FVC) Baseline, month 3, 6 , 9, 12, 18, and 24 millilitre,Acute exacerbation rate Baseline, month 3, 6 , 9, 12, 18, and 24 percent,Time to first exacerbation Baseline, month 3, 6 , 9, 12, 18, and 24 week | — |
Secondary
| Measure | Time frame |
|---|---|
| Co-morbidities Baseline, month 3, 6 , 9, 12, 18, and 24 percent,mortality Baseline, month 3, 6 , 9, 12, 18, and 24 percent,Change of respiratory symptom and quality of life Baseline, month 3, 6 , 9, 12, 18, and 24 unit,Cost of IPF management Baseline, month 3, 6 , 9, 12, 18, and 24 Baht | — |
Countries
Thailand
Contacts
Public ContactSupparerk Disayabutr
Faculty of Medicine Siriraj Hospital, Mahidol University
Outcome results
None listed